IDH Mutations in Human Glioma

Neurosurgery Clinics of North America

Volumn 23, Issue 3, 2012, Pages 471-480

  Kim, Won ^a   Liau, Linda M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

Brain tumor; GBM; Glioma; IDH1; IDH2; Isocitrate dehydrogenase

Indexed keywords

AMINO ACID SEQUENCE; CANCER DIAGNOSIS; CANCER GRADING; CARCINOGENESIS; CHROMOSOME DELETION; CHROMOSOME DELETION 1P19Q; DIFFERENTIAL DIAGNOSIS; GENE; GENE MUTATION; GLIOMA; GLIOMAGENESIS; HISTOPATHOLOGY; HUMAN; ISOCITRATE DEHYDROGENASE 1 GENE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TP53 GENE; TUMOR CLASSIFICATION;

BRAIN NEOPLASMS; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; PROGNOSIS;

EID: 84862999702     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.04.009     Document Type: Review

References (89)

1. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97.
2. Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005, 64:479.
3. Okamoto Y., Di Patre P.L., Burkhard C., et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 2004, 108:49.
4. Figarella-Branger D., Colin C., Coulibaly B., et al. Rev Neurol (Paris) 2008, 164:505. [in French].
5. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807.
6. Reitman Z.J., Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 2010, 102:932.
7. Antonelli M., Buttarelli F.R., Arcella A., et al. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol 2010, 99:209.
8. Balss J., Meyer J., Mueller W., et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008, 116:597.
9. Bleeker F.E., Lamba S., Leenstra S., et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009, 30:7.
10. Christensen B.C., Smith A.A., Zheng S., et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst 2011, 103:143.
11. Dubbink H.J., Taal W., van Marion R., et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009, 73:1792.
12. Gravendeel L.A., Kloosterhof N.K., Bralten L.B., et al. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat 2010, 31:E1186.
13. Gravendeel L.A., Kouwenhoven M.C., Gevaert O., et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 2009, 69:9065.
14. Hartmann C., Hentschel B., Tatagiba M., et al. Molecular markers in low-grade gliomas: predictive or prognostic?. Clin Cancer Res 2011, 17:4588.
15. Hartmann C., Hentschel B., Wick W., et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010, 120:707.
16. Hartmann C., Meyer J., Balss J., et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009, 118:469.
17. Houillier C., Wang X., Kaloshi G., et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010, 75:1560.
18. Ichimura K., Pearson D.M., Kocialkowski S., et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009, 11:341.
19. Jones D.T., Mulholland S.A., Pearson D.M., et al. Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts. Acta Neuropathol 2011, 121:753.
20. Kang M.R., Kim M.S., Oh J.E., et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 2009, 125:353.
21. Korshunov A., Meyer J., Capper D., et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 2009, 118:401.
22. Labussiere M., Idbaih A., Wang X.W., et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 2010, 74:1886.
23. Metellus P., Coulibaly B., Colin C., et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 2010, 120:719.
24. Nobusawa S., Watanabe T., Kleihues P., et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009, 15:6002.
25. Watanabe T., Nobusawa S., Kleihues P., et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009, 174:1149.
26. Watanabe T., Vital A., Nobusawa S., et al. Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol 2009, 117:653.
27. Pollack I.F., Hamilton R.L., Sobol R.W., et al. IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv Syst 2011, 27:87.
28. Sanson M., Marie Y., Paris S., et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009, 27:4150.
29. Taal W., Dubbink H.J., Zonnenberg C.B., et al. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neuro Oncol 2011, 13:235.
30. Takano S., Tian W., Matsuda M., et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 2011, 28:115.
31. Toedt G., Barbus S., Wolter M., et al. Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer 2011, 128:1095.
32. van den Bent M.J., Dubbink H.J., Marie Y., et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010, 16:1597.
33. Weller M., Felsberg J., Hartmann C., et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009, 27:5743.
34. Wick W., Hartmann C., Engel C., et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009, 27:5874.
35. Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765.
36. Zhao S., Lin Y., Xu W., et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324:261.
37. Reitman Z.J., Olby N.J., Mariani C.L., et al. IDH1 and IDH2 hotspot mutations are not found in canine glioma. Int J Cancer 2010, 127:245.
38. Winkler B.S., DeSantis N., Solomon F. Multiple NADPH-producing pathways control glutathione (GSH) content in retina. Exp Eye Res 1986, 43:829.
39. Narahara K., Kimura S., Kikkawa K., et al. Probable assignment of soluble isocitrate dehydrogenase (IDH1) to 2q33.3. Hum Genet 1985, 71:37.
40. Yen K.E., Bittinger M.A., Su S.M., et al. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 2010, 29:6409.
41. Xu X., Zhao J., Xu Z., et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem 2004, 279:33946.
42. Dang L., White D.W., Gross S., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010, 465:966.
43. Kloosterhof N.K., Bralten L.B., Dubbink H.J., et al. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?. Lancet Oncol 2011, 12:83.
44. Pusch S., Sahm F., Meyer J., et al. Glioma IDH1 mutation patterns off the beaten track. Neuropathol Appl Neurobiol 2011, 37:428.
45. Ward P.S., Patel J., Wise D.R., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225.
46. Dang L., Jin S., Su S.M. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 2010, 16:387.
47. Capper D., Weissert S., Balss J., et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010, 20:245.
48. Jha P., Suri V., Sharma V., et al. IDH1 mutations in gliomas: first series from a tertiary care centre in India with comprehensive review of literature. Exp Mol Pathol 2011, 91:385.
49. Horbinski C., Kofler J., Yeaney G., et al. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol 2011, 21:564.
50. Sonoda Y., Kumabe T., Nakamura T., et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 2009, 100:1996.
51. von Deimling A., Korshunov A., Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 2011, 21:74.
52. Camelo-Piragua S., Jansen M., Ganguly A., et al. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol 2011, 70:110.
53. Capper D., Reuss D., Schittenhelm J., et al. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol 2011, 121:241.
54. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721.
55. King A., Selak M.A., Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 2006, 25:4675.
56. Williams S.C., Karajannis M.A., Chiriboga L., et al. R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1alpha upregulation in adult glioma. Acta Neuropathol 2011, 121:279.
57. Thompson C.B. Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med 2009, 360:813.
58. Jin G., Reitman Z.J., Spasojevic I., et al. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One 2011, 6:e16812.
59. Seltzer M.J., Bennett B.D., Joshi A.D., et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010, 70:8981.
60. Xu W., Yang H., Liu Y., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17.
61. Bralten L.B., Kloosterhof N.K., Balvers R., et al. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol 2011, 69:455.
62. Reitman Z.J., Jin G., Karoly E.D., et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A 2011, 108:3270.
63. Moroni I., Bugiani M., D'Incerti L., et al. L-2-hydroxyglutaric aciduria and brain malignant tumors: a predisposing condition?. Neurology 2004, 62:1882.
64. Struys E.A. D-2-Hydroxyglutaric aciduria: unravelling the biochemical pathway and the genetic defect. J Inherit Metab Dis 2006, 29:21.
65. Struys E.A., Salomons G.S., Achouri Y., et al. Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. Am J Hum Genet 2005, 76:358.
66. Frezza C., Tennant D.A., Gottlieb E. IDH1 mutations in gliomas: when an enzyme loses its grip. Cancer Cell 2010, 17:7.
67. Nikiforova M.N., Hamilton R.L. Molecular diagnostics of gliomas. Arch Pathol Lab Med 2011, 135:558.
68. Bourne T.D., Schiff D. Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol 2010, 6:695.
69. Ducray F., El Hallani S., Idbaih A. Diagnostic and prognostic markers in gliomas. Curr Opin Oncol 2009, 21:537.
70. Kim Y.H., Nobusawa S., Mittelbronn M., et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol 2010, 177:2708.
71. Felsberg J., Wolter M., Seul H., et al. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 2010, 119:501.
72. Jha P., Suri V., Jain A., et al. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment. Neurosurgery 2010, 67:1681.
73. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061.
74. Noushmehr H., Weisenberger D.J., Diefes K., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510.
75. Laffaire J., Everhard S., Idbaih A., et al. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol 2011, 13:84.
76. Verhaak R.G., Hoadley K.A., Purdom E., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98.
77. Ducray F., Mokhtari K., Criniere E., et al. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. Eur J Cancer 2011, 47:802.
78. Mokhtari K., Ducray F., Kros J.M., et al. Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951. Cancer 2011, 117:3014.
79. Setty P., Hammes J., Rothamel T., et al. A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. J Mol Diagn 2010, 12:750.
80. Meyer J., Pusch S., Balss J., et al. PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol 2010, 20:298.
81. Boisselier B., Marie Y., Labussiere M., et al. COLD PCR HRM: a highly sensitive detection method for IDH1 mutations. Hum Mutat 2010, 31:1360.
82. Horbinski C., Kelly L., Nikiforov Y.E., et al. Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn 2010, 12:487.
83. Kato Y., Jin G., Kuan C.T., et al. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 2009, 390:547.
84. Preusser M., Wohrer A., Stary S., et al. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol 2011, 70:715.
85. Gupta R., Webb-Myers R., Flanagan S., et al. Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. J Clin Pathol 2011, 64:835.
86. Ikota H., Nobusawa S., Tanaka Y., et al. High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein. Brain Tumor Pathol 2011, 28:107.
87. Kaneko M.K., Tian W., Takano S., et al. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem Biophys Res Commun 2011, 406:608.
88. De Carli E., Wang X., Puget S. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:2248. [author reply: 2249].
89. Reitman Z.J., Parsons D.W., Yan H. IDH1 and IDH2: not your typical oncogenes. Cancer Cell 2010, 17:215.